Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI scores Ceribell, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Ceribell, Inc. is a small-cap company with a market capitalization of $998M. It ranks number 7 by market capitalization among the 28 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast. Its Gross Margin of 89.3% is the highest of the 25 peers that report one.
For CBLL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 57.0%, measured on 240 forecast dates between 2024-11-15 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 36.0%, measured on 283 forecast dates between 2024-11-15 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.3%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CBLL included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
| Metric | CBLL | Rank |
|---|---|---|
| Market Cap | $998M | 7/28 |
| P/B Ratio | 8.49x | 5/22 |
| EPS | $-2.15 | – |
| Book Value/Share | $3.06 | – |
| Revenue/Share | $2.83 | – |
| FCF/Share | $-1.47 | – |
| Metric | CBLL | Rank |
|---|---|---|
| ROE | -62.9% | 10/16 |
| ROA | -47.2% | 12/19 |
| ROIC | -54.8% | 16/20 |
| Gross Margin | 89.3% | 1/25 |
| Operating Margin | -69.8% | 17/25 |
| Net Margin | -68.0% | 13/18 |
| EBT Margin | -68.0% | 16/25 |
| Metric | CBLL | Rank |
|---|---|---|
| Current Ratio | 8.18x | 4/27 |
| Quick Ratio | 7.79x | 4/26 |
| D/E Ratio | 0.33x | 18/23 |
| Financial Leverage | 1.33x | 19/23 |
| Interest Coverage | -77.0x | 19/27 |
| Working Capital | $129M | 9/26 |
| Metric | CBLL | Rank |
|---|---|---|
| Operating Cash Flow | -$56M | 27/27 |
| Free Cash Flow | -$56M | 14/14 |
| Capital Spending | -$420K | 5/14 |
| FCF/Sales | -51.9% | 11/14 |
| CapEx/Sales | 0.4% | 13/14 |
| Metric | CBLL | Rank |
|---|---|---|
| Asset Turnover | 0.70x | 7/17 |
| Receivables Turnover | 6.1x | 9/19 |
| Inventory Turnover | 1.7x | 14/25 |
| Fixed Assets Turnover | 61.3x | 3/19 |
| Days Sales Outstanding | 60 days | 11/19 |
| Days Inventory | 217 days | 12/25 |
| Payables Period | 73 days | 13/23 |
| Cash Conversion Cycle | 204 days | 6/18 |
| Metric | CBLL | Rank |
|---|---|---|
| Total Revenue | $109M | 7/18 |
| Operating Income | -$76M | 27/27 |
| Net Income | -$74M | 19/20 |
| R&D Expense | $25M | 7/26 |
| SG&A Expense | $193M | 8/24 |
| Cost of Goods Sold | $12M | 15/25 |
| Metric | CBLL | Rank |
|---|---|---|
| Shares Outstanding | 38M | – |
| Total Current Assets | $147M | 94.3% of assets |
| Cash & Short-term Investments | $42M | 26.8% of assets |
| Accounts Receivable | $18M | 11.4% of assets |
| Inventory | $7M | 4.4% of assets |
| Total Liabilities | $39M | 24.8% of assets |
| Short-term Debt | $16M | 10.0% of assets |
Companies classified under the same SEC industry code as Ceribell, Inc. (Electromedical & Electrotherapeutic Apparatus): 29 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CBLL Ceribell, Inc. | $998M | |
| MDT Medtronic Plc | $134.10B | |
| LIVN Livanova Plc | $5.02B | |
| ITGR Integer Holdings Corp | $4.31B | |
| AXGN Axogen, Inc. | $2.91B | |
| TMDX Transmedics Group, Inc. | $2.39B | |
| CNMD Conmed Corp | $1.57B | |
| INMD Inmode Ltd. | $770M | |
| CV Capsovision, Inc | $310M | |
| ELMD Electromed, Inc. | $224M | |
| FOCL Edap Tms Sa | $159M | |
| STXS Stereotaxis, Inc. | $105M | |
| VANI Vivani Medical, Inc. | $95M | |
| ECOR Electrocore, Inc. | $79M | |
| OM Outset Medical, Inc. | $78M | |
| NRXS Neuraxis, Inc | $77M | |
| HYPR Hyperfine, Inc. | $73M | |
| POSC Positron Corp | $55M | |
| POCI Precision Optics Corporation, Inc. | $51M | |
| QTI Qt Imaging Holdings, Inc. | $32M | |
| ITOC Itonic Holdings Ltd | $12M | |
| IRIX Iridex Corp | $12M | |
| GTHP Guided Therapeutics Inc | $10M | |
| NDRA Endra Life Sciences Inc. | $7M | |
| ADMT Adm Tronics Unlimited, Inc. | $6M | |
| NUWE Nuwellis, Inc. | $2M | |
| ESMC Escalon Medical Corp | $1M | |
| NXL Nexalin Technology, Inc. | $1M | |
| YBGJ Yubo International Biotech Ltd | N/A |
CeriBell, Inc. (CBLL) reported $29.34 million in revenue for the quarter ended September 2026, representing a year-over-year increase of 29.9%. EPS of -$0.48 for the same period compares to -$0.37 a ...
Full year 2026 revenue guidance was narrowed to $115 million to $117 million, which notably excludes material contributions ...
CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.37 per share a year ago. These figures are ...
Our AI scores Ceribell, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For CBLL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 57.0%, measured on 240 forecast dates between 2024-11-15 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 36.0%, measured on 283 forecast dates between 2024-11-15 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Ceribell, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
29 issuers in our coverage, CBLL included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Livanova Plc (LIVN), Integer Holdings Corp (ITGR), Axogen, Inc. (AXGN), Transmedics Group, Inc. (TMDX), Conmed Corp (CNMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
